Insider · CIK 0002016615
Daniel J. Antal
officer
Files at LDOS (Leidos Holdings, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | LDOS Leidos Holdings, Inc. | AGrant or award Common Stockindirect: By Key Executive Stock Deferral Plan | +5 | $0.00 | $0 | 10,747 | 10 d ago |
| May 3, 2025 | LDOS Leidos Holdings, Inc. | FTax withholding Common Stock | -194 | $148.79 | $29k | 13,047 | May 6, 2025 |
| May 3, 2025 | LDOS Leidos Holdings, Inc. | FTax withholding Common Stockindirect: By Key Executive Stock Deferral Plan | -18 | $148.79 | $2,678 | 5,002 | May 6, 2025 |
| May 3, 2025 | LDOS Leidos Holdings, Inc. | AGrant or award Common Stockindirect: By Key Executive Stock Deferral Plan | +4 | $0.00 | $0 | 5,006 | May 6, 2025 |
| Mar 7, 2025 | LDOS Leidos Holdings, Inc. | AGrant or award Common Stock | +3,758 | $0.00 | $0 | 13,241 | Mar 11, 2025 |
| Mar 7, 2025 | LDOS Leidos Holdings, Inc. | AGrant or award Common Stockindirect: By Key Executive Stock Deferral Plan | +3,758 | $0.00 | $0 | 5,020 | Mar 11, 2025 |
| Mar 7, 2025 | LDOS Leidos Holdings, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +8,169 | $0.00 | $0 | 8,169 | Mar 11, 2025 |
| Feb 6, 2025 | LDOS Leidos Holdings, Inc. | AGrant or award Common Stock | +1,262 | $0.00 | $0 | 9,483 | Feb 10, 2025 |
| Feb 6, 2025 | LDOS Leidos Holdings, Inc. | AGrant or award Common Stockindirect: KESDP | +1,262 | $0.00 | $0 | 1,262 | Feb 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.